Medtronic plcMDT commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This happened following the U.S. FDA approval late last year.

Medtronic's MiniMed 670G could reduce the burden on Type 1 diabetes patients, as well as slow diabetes progression by keeping blood glucose levels on target. There are about 1.25 million Americans ...

Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...

Roughly 1.25 million Americans have Type 1 diabetes, so chances are you know somebody whose pancreas is taking the world’s longest lunch break. That person may be you. As it happens, there has never ...

The approval of Medtronic's Minimed 670G could reshape the type 1 treatment market next year, but I wouldn't count DexCom out. Its best-in-class technology could position it to capture a significant ...

Medtronic touted new clinical data from its growing base of MiniMed 670G insulin-pump users, noting on Tuesday that people who used the pump's most advanced features kept their blood sugar levels ...

Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...

Value-based care and paying for performance are not the order of the day yet, but incremental moves are being made to move away from a fee-for-service world. The latest evidence of it comes from ...

The FDA announced that Medtronic expanded two recalls relating to the MiniMed 600 series of insulin pumps and MiniMed 508 remote controllers. Both were designated by the agency as Class I, the most ...

Sales of the company’s MiniMed 670G device, which is the med-tech giant's latest “artificial pancreas” system, partly drove the diabetes division's strong performance. Medtronic reported earnings that ...